Bio-Rad and the University of Chicago sued 10X Genomics for infringing U.S. Patent Nos. 8,889,083, 8,304,193, and 8,329,407, which relate to genetic analysis tools. The jury found all three patents valid and infringed and that Plaintiffs are entitled to $23,930,817 in damages.
The court entered final judgment for $34,475,069, which included the verdict award, more than $8 million in supplemental damages through the date of the verdict, and over $2 million in interest.
The court separately enjoined 10X from using or selling its Chromium Genome/Exome, GemCode Long Read, Chromium Single Cell 3’, or Chromium Single Cell V(D)J systems, but permitted 10X to sell consumables for the installed base of these products. The court severed and stayed a determination of a royalty for 10X’s sale of those consumables, but ordered that 10X put into escrow a 15% royalty on 10X’s net revenue from such sales.
The case is Bio-Rad Laboratories, Inc. and The University of Chicago v. 10X Genomics, Inc., No. 15-cv-152-RGA (D. Del.)